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ABSTRACT
The immune-modulating properties of certain bifidobacterial strains, such as Bifidobacterium longum subsp. longum 35624 (B.
longum 35624), have been well described, although the strain-specific molecular characteristics associated with such immune-
regulatory activity are not well defined. It has previously been demonstrated that B. longum 35624 produces a cell surface exopo-
lysaccharide (sEPS), and in this study, we investigated the role played by this exopolysaccharide in influencing the host immune
response. B. longum 35624 induced relatively low levels of cytokine secretion from human dendritic cells, whereas an isogenic
exopolysaccharide-negative mutant derivative (termed sEPSneg) induced vastly more cytokines, including interleukin-17 (IL-17),
and this response was reversed when exopolysaccharide production was restored in sEPSneg by genetic complementation. Ad-
ministration of B. longum 35624 to mice of the T cell transfer colitis model prevented disease symptoms, whereas sEPSneg did
not protect against the development of colitis, with associated enhanced recruitment of IL-17 lymphocytes to the gut. More-
over, intranasal administration of sEPSneg also resulted in enhanced recruitment of IL-17 lymphocytes to the murine lung.
These data demonstrate that the particular exopolysaccharide produced by B. longum 35624 plays an essential role in dampen-
ing proinflammatory host responses to the strain and that loss of exopolysaccharide production results in the induction of local
TH17 responses.
IMPORTANCE
Particular gut commensals, such as B. longum 35624, are known to contribute positively to the development of mucosal immune
cells, resulting in protection from inflammatory diseases. However, the molecular basis andmechanisms for these commensal-
host interactions are poorly described. In this report, an exopolysaccharide was shown to be decisive in influencing the immune
response to the bacterium.We generated an isogenic mutant unable to produce exopolysaccharide and observed that this muta-
tion caused a dramatic change in the response of human immune cells in vitro. In addition, the use of mouse models confirmed
that lack of exopolysaccharide production induces inflammatory responses to the bacterium. These results implicate the surface-
associated exopolysaccharide of the B. longum 35624 cell envelope in the prevention of aberrant inflammatory responses.
The gut microbiota contributes significantly to host health viamultiple mechanisms, including the digestion of foods, com-
petitive exclusion of pathogens, enhancement of epithelial cell dif-
ferentiation, and promotion of mucosa-associated lymphoid tis-
sue proliferation (1, 2). Furthermore, accumulating evidence
suggests that the composition and metabolic activity of the gut
microbiota has profound effects on proinflammatory activity and
the induction of immune tolerance within mucosal tissue (3–5).
Certain microbes induce regulatory responses, while others in-
duce effector responses, resulting in the case of healthy individuals
in a balanced homeostatic immunological state that protects
against infection and controls aberrant, tissue-damaging inflam-
matory responses (6).
One bacterial strain that is known to induce tolerogenic re-
sponses within the gut is Bifidobacterium longum subsp. longum
35624 (7). Induction of T regulatory (Treg) cells by the B. longum
35624 strain in mice is associated with protection against colitis,
arthritis, allergic responses, and pathogen-associated inflamma-
tion (8–12). Administration of this bacterium to humans in-
creases Foxp3 lymphocytes in peripheral blood, enhances inter-
leukin-10 (IL-10) secretion ex vivo, and reduces the levels of
circulating proinflammatory biomarkers in a wide range of pa-
tient groups (13, 14). A number of host mechanisms that contrib-
ute to the anti-inflammatory activity of this microbe have been
described, including Toll-like receptor 2 (TLR-2) and dendritic
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cell-specific intercellular adhesion molecule-3-grabbing nonin-
tegrin (DC-SIGN) recognition and retinoic acid release by den-
dritic cells (13, 15–17). However, the bacterial-strain-specific
structural and/or metabolic factors that contribute to these pro-
tective immune responses have as yet remained elusive.
A number of different exopolysaccharides (EPS) from gut mi-
crobes have been shown to induce immune-modulatory effects.
PolysaccharideA (PSA) fromBacteroides fragilismediates the con-
version of naive CD4 T cells into Foxp3 Treg cells that produce
IL-10 during commensal colonization. Functional Treg cells are
also induced by PSA during intestinal inflammation, which re-
quires TLR-2 signaling (18). Further studies have reported that
PSA interacts directly with mouse plasmacytoid dendritic cells via
TLR-2 and that PSA-exposed plasmacytoid dendritic cells express
molecules involved in protection against colitis and stimulate
CD4 T cells to secrete IL-10 (19). An exopolysaccharide from
Bacillus subtilis prevents gut inflammation stimulated by Citro-
bacter rodentium, which is dependent on TLR-4 and MyD88 sig-
naling (20). Similarly, protection against C. rodentium infection
byBifidobacteriumbreveUCC2003was dependent on the presence
of its exopolysaccharide (21). Furthermore, it was described that
an extracellular polymeric matrix, isolated from Faecalibacterium
prausnitzii, displayed anti-inflammatory activity in the mouse
dextran sodium sulfate colitis model (22).
We recently described that the B. longum 35624 strain-specific
EPS gene cluster, designated the EPS624 cluster, is responsible for
the production of a cell surface-associated exopolysaccharide
(sEPS) composed of a branched hexasaccharide repeating unit
with two galactoses, two glucoses, galacturonic acid, and the un-
usual sugar 6-deoxytalose (23). The overall aim of the current
study was to determine whether the exopolysaccharide produced
by B. longum 35624 is related to the immunoregulatory effects of
this microorganism. To address this aim, we investigated whether
an isogenic derivative of B. longum 35624 that does not produce
exopolysaccharide, designated sEPSneg, is able to exert immuno-
logical effects similar to those of its parent strain in vitro and in
colitis and asthma mouse models.
MATERIALS AND METHODS
Bacterial strains, plasmids, and culture conditions.The bacterial strains
and plasmids used in this study are detailed in Table 1. Bifidobacteria were
routinely cultured in either deMan Rogosa Sharpemedium (MRS; Oxoid
Ltd., Basingstoke, United Kingdom) supplemented with 0.05% cysteine–
HCl or reinforced clostridial medium (RCM;Oxoid Ltd.). Bifidobacterial
cultures were incubated at 37°C under anaerobic conditions in a Don
Whitley anaerobic chamber. Escherichia coli strains were cultured in ly-
sogeny broth (LB; Oxoid Ltd.) at 37°C with agitation.Where appropriate,
the growth medium contained chloramphenicol (Cm; 10 g ml1 for E.
coli and 5gml1 for B. longum 35624), erythromycin (Em; 100gml1
for E. coli), tetracycline (Tet; 10 g ml1 for E. coli and 10 g ml1 for B.
longum 35624), ampicillin (Amp; 100 g ml1 for E. coli), or kanamycin
(Km; 50 g ml1 for E. coli). All antibiotics were obtained from Sigma-
Aldrich (England). The commercially available B. longum 35624 culture
was provided by Alimentary Health Limited (Cork, Ireland).
DNA manipulations. Chromosomal DNA was isolated from bifido-
bacteria as previously described (24). Preparation of plasmid DNA from
E. coli or B. longum 35624 was achieved using the QIAprep spin plasmid
miniprep kit (QiagenGmBH,Hilden, Germany). ForB. longum 35624, an
initial lysis step was incorporated into the plasmid isolation procedure,
and cells were resuspended in lysis buffer supplemented with lysozyme
(30 mgml1) and incubated at 37°C for 30 min. Restriction enzymes and
T4 DNA ligase were used according to the supplier’s instructions (Roche
Diagnostics, UnitedKingdom). The synthetic single-stranded oligonucle-
otide primers used in this study were obtained from Eurofins (Ebersberg,
Germany) and are detailed in Table 2. Standard PCRs were performed
usingTaqPCRmastermix (Qiagen), while high-fidelity PCRwas achieved
using PfuII polymerase (Agilent, Santa Clara, CA). B. longum 35624 col-
ony PCRs were performed according to standard procedures with the
addition of an initial incubation step of 95°C for 5 min to perform cell
lysis. PCR fragments were purified using the Qiagen PCR purification kit.
Following electroporation of plasmid DNA into E. coli strain EC101, elec-
trotransformation of B. longum 35624 or sEPSneg was performed essen-
tially as described byMaze et al. (25) with the followingmodifications. An
overnight culture of B. longum 35624 was subcultured twice (first using a
2% inoculum and then a 1% inoculum) in MRS medium supplemented
with 0.05% cysteine–HCl and 0.2 M sucrose prior to inoculating (4%)
modified Rogosa medium supplemented with 0.05% cysteine–HCl, 1%
(wt/vol) glucose, and 0.2M sucrose. Bacteria were grown until the optical
density at 600 nm (OD600) had reached 0.3 to 0.4, after which cells were
harvested by centrifugation (6,500 rpm for 10 min at 4°C) and washed
twice using 1 mM ammonium citrate buffer (pH 6.0) supplemented with
0.5 M sucrose. An additional centrifugation step (9,800 g for 10 min at
4°C) was included to concentrate the competent cells. For electropora-
tion, 5 l of plasmid DNA was mixed with 50 l of competent cells,
transferred into an electroporation cuvette with a 0.2-cm interelectrode
distance, and pulsed at 2.5 kV, 25 F, and 200  using a Gene Pulser II
electroporation system (Bio-Rad, Hercules, CA). For recovery, 800 l of
TABLE 1 Bacterial strains and plasmids used in this study
Strain or plasmid Relevant characteristics Reference or source
Strains
E. coli EC101 Cloning host, repA negative, Kmr 26
E. coli XL1 Blue Cloning host, Tetr Stratagene
E. coli EC101/pNZ-M.1185 E. coli EC101 harboring pNZ-M.1185 This study
B. longum 35624 Parent strain Alimentary Health
sEPSneg B. longum 35624 harboring insertion mutation in priming glycosyl transferase-encoding gene pgt624 This study
sEPScomp sEPSneg harboring pBC1.2_pgt624BI0343 This study
Plasmids
pNZEm Gene expression vector, Emr 55
pORI19 Emr, repA negative, ori, cloning vector 26
pORI19tet(W)_pgt pORI19 harboring internal fragment of BI0342 (pgt) and TetW gene This study
pBC1.2 E. coli-Bifidobacterium shuttle vector 27
pBC1.2_pgt624BI0343 pBC1.2 harboring the cotranscribed genes pgt624 and BI0343 under the control of their native promoter This study
pNZ-M.1185 BI1185 (M.1185, isoschizomer of M.EcoRII) cloned with its own promoter in pNZEM This study
Schiavi et al.
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RCM supplemented with 0.05% L-cysteine hydrochloride was added to
the bacteria and they were incubated anaerobically for 2.5 h at 37°C.
Transformants were plated on reinforced clostridial agar (RCA) plates
supplementedwith appropriate concentrations of relevant antibiotics and
incubated for 2 to 3 days anaerobically at 37°C. The correct orientation
and integrity of all constructs was verified by PCR and subsequent DNA
sequencing, which was performed at Eurofins (Ebersberg, Germany).
Construction of sEPSneg. An internal 583-bp fragment of the pgt624
gene was amplified by PCR using B. longum 35624 chromosomal DNA as
a template and the oligonucleotide primers BI0342F_HindIII and
BI0342R_XbaI. The PCR product generated was ligated to pORI19, an
OriRepA integration plasmid (26), using the uniqueHindIII andXbaI
restriction sites that were incorporated into the primers for the pgt frag-
ment-encompassing amplicon, and the plasmid introduced into E. coli
EC101 by electroporation. Recombinant E. coli EC101 derivatives con-
taining pORI19 constructs were selected on LB agar containing Em and
supplemented with X-Gal (5-bromo-4-chloro-3-indolyl--D-galactopy-
ranoside) (40 g ml1) and IPTG (isopropyl--D galactopyranoside) (1
mM). The expected genetic structure of the recombinant plasmid, desig-
nated pORI19-pgt, was confirmed by restriction mapping prior to sub-
cloning of the Tet resistance antibiotic cassette, tet(W), from pAM5 (27)
as a SacI fragment into the unique SacI site on pORI19-pgt. The expected
structure of a single representative of the resulting plasmid, designated
pORI19tet(W)_pgt, was confirmed by restriction analysis. The plasmid
was introduced into E. coli EC101 harboring pNZ-M.1185 (this is a plas-
mid expressing a B. longum 35624-encoded methylase) by electropora-
tion, and transformants were selected based on Em and Tet resistance.
Methylation of the resulting plasmid complement of such transformants
by M.1185 (isoschizomer of M.EcoRII) was confirmed by their observed
resistance to EcoRII restriction. Plasmid preparations of methylated
pORI19tet(W)_pgt were introduced by electroporation into B. longum
35624 with subsequent selection on RCA plates supplemented with Tet.
Construction of sEPScomp. For the construction of plasmid pBC1.2_
pgt624BI0343, a DNA fragment encompassing pgt624 plus the gene with
locus tag BI0343 located downstream and the presumed promoter region,
was generated by PCR amplification from chromosomal DNA of B. longum
35624 using PfuII polymerase and primer combinations BI0342FSalI and
BI0343EcoRI, where SalI or EcoRI restriction sites were incorporated at
the 5= ends of the forward primer and reverse primer, respectively. Am-
plicons were digested with SalI and EcoRI and ligated into similarly di-
gested pBC1.2 prior to introduction into E. coli XL1 Blue by electropora-
tion and subsequent selection of transformants on LB agar supplemented
with Tet and Amp. The integrity of positive clones was confirmed by
sequencing, and one selected clone, designated pBC1.2 pgtBI0343,
was introduced into sEPSneg by electroporation with subsequent selec-
tion of transformants on RCA supplemented with Tet and Cm. The re-
sultant complemented sEPSneg strain, harboring pBC1.2_pgtBI0343,
was designated sEPScomp.
Electron microscopy. After culture in MRS medium, bacteria were
gently rinsed in PIPES (piperazine-N,N-bis-2-ethane sulfonic acid) buffer
(0.1M, pH 7.4) before being fixed in 2.5% glutaraldehyde in PIPES buffer
for 5 min. The samples were rinsed twice (2 min each time) in PIPES
buffer and postfixed with 1% osmium tetroxide in 0.1 M PIPES buffer
(pH 6.8) for 60 min in the dark. The samples were rinsed three times in
double-distilled water (2 min each wash) before being dehydrated
through an ethanol series (50, 70, 96, and 100%) for 5 min each step. All
fixation and washing steps were carried out at room temperature. Follow-
ing dehydration, the samples were critically point dried in a Polaron
E3100 critical point drier (Agar Scientific, Stansted, United Kingdom)
and coated with 10 nmof gold/palladium (80/20) using a BaltecMED 020
unit (Baltec, Buchs, Liechtenstein). Bacterial preparations were examined
using a Hitachi S-4700 scanning electron microscope (SEM) operated in
secondary electron detection mode (3 kV, 40 A), and images captured
with Quartz PCI (Quartz Imaging Corporation, Vancouver, Canada).
Exopolysaccharide isolation. The exopolysaccharide was isolated as
previously described (23). Briefly, following harvesting of B. longum
35624 cells, which were grown on agar plates to minimize carryover of
medium components, an exopolysaccharide solution was generated by
agitating the cells in phosphate-buffered saline (PBS). The harvested ex-
opolysaccharide solutionwasmixedwith ethanol, and the exopolysaccha-
ride aggregated at the center of the surface of the ethanol solution, which
facilitated harvesting of the exopolysaccharide without the need for cen-
trifugation. The exopolysaccharide aggregations were taken with a spat-
ula, resuspended in water and dialyzed against water to remove contam-
inants and residual ethanol. The exopolysaccharidewas applied 2 times on
Bakerbond SPE C18 columns (Avantor, Deventer, The Netherlands) as
indicated by the manufacturer using a HyperSep-96 vacuum manifold
(Thermo Scientific, Waltham, MA). The flowthrough fraction was col-
lected and filtered through 0.45-m syringe filters. Quantification of total
carbohydrate levels was performed as previously described (28) using a
phenol-sulfuric acid method in microplate format. The absence of con-
taminating proteins was confirmed bymeasuring the total soluble protein
content of the exopolysaccharide preparation using the bicinchoninic
acid (BCA) protein quantification kit (Thermo Scientific) according to
the manufacturer’s instructions. Bovine serum albumin was used to gen-
erate standards. Lipopolysaccharide (LPS) contamination was monitored
using the PyroGene recombinant factor C assay (Lonza, Bettlach, Switzer-
land).
In vitro immune assays.Human blood was purchased from the Swiss
blood bank (Blutspendezentrum, Basel, Switzerland), which obtains
the blood following appropriate screening and with the consent of volun-
teers. Blood samples were anonymized and coded prior to leaving the
blood bank. Research procedures on human blood were performed in
accordance with Swiss law (ethical approval number KEK Nr. 19/08). All
experiments with human blood-derived cells were conducted under bio-
safety level 2 conditions. Peripheral blood mononuclear cells (PBMCs)
were isolated from healthy donors using density gradient centrifugation.
Human monocyte-derived dendritic cells (MDDCs) were differentiated
with 1,000 IU ml1 granulocyte-macrophage colony-stimulating factor
(GM-CSF; Peprotech, London,UnitedKingdom) and 1,000 IUml1 IL-4
(Novartis, Basel, Switzerland) from purified CD14 cells using magneti-
cally activated cell sorting (MACS) separation (Miltenyi Biotec, Bergisch
Gladbach, Germany). Bacterial strains for in vitro assays were cultured in
MRSmedium supplemented with 0.05% L-cysteine for 48 h under anaer-
TABLE 2 Oligonucleotide primers used in this study
Purpose Primer Sequencea
Cloning of M.1185 in pNZEm BI1185F_PstI GACTGCAGGCCCACTAGGTAACCAAACG
BI1185R_SpeI GCGCACTAGTCTAGAGCAAAGCCAGTATAG
Cloning of internal 583-bp fragment of pgt in pORI19 BI0342F_HindIII GATAAGCTTGCGTCGGCAACTCAACTACC
BI0342R_XbaI GATTCTAGACGTCGGCGTTCACTACCATC
Cloning of pgt624 and BI0343 in pBC1.2 BI0342FSalI GACGTCGACACTCCACTCTCGCTGATCG
BI0343EcoRI GGCGAATTCTAATCAACCAAGGGGGTCTG
a Restriction sites incorporated into oligonucleotide primer sequences are indicated in boldface.
B. longum Exopolysaccharide Modulates TH17 Responses
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obic conditions at 37°C. Cells were harvested andwashed oncewith sterile
PBS by centrifugation at 6,500 rpm for 10 min. Bacterial cell numbers
were determined by microscopy using a Petroff-Hausser chamber, and
bacteria were diluted as appropriate in PBS for incubation with human
cells. PBMCs andMDDCs were stimulated for 24 h at 37°C, 5%CO2 with
bacterial strains at a concentration of 50 bacterial cells to 1 PBMC or
MDDC.Human and bacterial cell cocultures were performed in complete
RPMI 1640 (cRPMI)medium (Sigma, Buchs, Switzerland) supplemented
with 10% fetal bovine serum (Sigma), penicillin (100 Uml1), and strep-
tomycin (0.1 mg ml1) (Sigma). Purified exopolysaccharide from B.
longum 35624 was also added (final concentration, 100 g/ml) to PBMC
cultures (in duplicate) stimulated with sEPSneg. Cytokine concentrations
were measured using the Bio-Plex multiplex system (Bio-Rad). For hu-
man dendritic cell staining, the following antibodies were used: phyco-
erythrin (PE)-Cy7 anti-human CD274 antibody (programmed death li-
gand-1 [PD-L1]), allophycocyanin (APC) anti-human CD273 antibody
(PD-L2), and Pacific blue anti-human CD11c antibody (eBioscience, Vi-
enna, Austria). The THP-1-Blue NF-B monocyte cell line (Invivogen,
San Diego, CA) was maintained and subcultured in cRPMI medium
(Sigma) in the presence of 200 g/ml Zeocin (Invivogen). For the cocul-
ture experiment with bacteria, 105 cells/well were seeded in a 96-well plate
in a total volume of 200 l/well of cRPMI medium. The cells were stim-
ulated over a range of different bacterial concentrations for 24 h, and
activation of the NF-B/AP-1 pathway was evaluated with the Quanti-
Blue assay according to the manufacturer’s instructions. In addition,
MDDCswere stimulatedwith different bacterial strains, andNF-Bphos-
phorylation measured over a time course. MDDCs were lysed using the
Bio-Plex Pro cell signaling reagent kit (Bio-Rad), and cell lysates were
stored at 80°C until analysis. Protein concentrations were determined
using Bio-Rad’s DC protein assay, and equal amounts of protein were
used to measure NF-B p65 (Ser536) in the Bio-Plex Pro magnetic cell
signaling assay (Bio-Rad). Results are expressed as mean fluorescence
intensity (MFI).
T cell transfer colitis model. C.B-17 severe combined immunodefi-
cient (SCID) and BALB/c female mice (8 to 12 weeks of age) were ob-
tained from Charles River (Sulzfeld, Germany) and maintained under
specific-pathogen-free conditions. The animals were housed at the AO
Research Institute, Davos, Switzerland, in individually ventilated cages for
the duration of the study, and all experimental procedures were carried
out in accordance with Swiss law (permit number 2013_32). Colitogenic
CD4 CD25 CD45RBhi cells were isolated from BALB/c donor mouse
spleens using the MACS Miltenyi system (depletion of CD4 CD25
cells, followed by positive selection of CD45RB fluorescein isothiocyanate
[FITC]-labeled cells). At day 0, colitis was induced by intraperitoneal
transfer of 4  105 cells per C.B-17 SCID mouse (8 mice per group).
Bacterial cells were prepared as described above and counted using mi-
croscopy (Petroff-Hausser chamber) prior to dilution in sterile PBS. An
amount of 1 109 B. longum 35624 cells or of one of its isogenic deriva-
tives was administered to eachmouse by intragastric gavage (total volume
of 200 l). Bacteria were gavaged from the beginning of the study (day 0)
and continued to be gavaged every second day until animals were eutha-
nized at the end of the study. Sixteen days after study initiation, disease
severity scores were recorded, while animal weights weremonitored every
day. Disease severity scores included the condition of feces (1, wet; 2,
diarrhea; and 3, bloody diarrhea or rectal prolapse), activity (1, isolated,
abnormal position; 2, huddled, hypoactive or hyperactive; and 3, uncon-
scious), coordination of movement (1, slightly uncoordinated; 2, very
uncoordinated; and 3, paralysis), and fur quality (1, reduced grooming; 2,
disheveled; and 3, hair loss). Gut transit was determined by quantifying
fecal B. longum 35624 levels by PCR. B. longum 35624-specific primers
were designed using Primer3 software (http://simgene.com/Primer3).
The primers, designated 2420t (forward, CAGTGGGGTGCGACTACA,
and reverse, GCG CGA ACC AGA AGA TGT), generated a 494-bp am-
plicon. Bacterial DNA from fecal samples was extracted using the
QIAamp DNA stool minikit (Qiagen). DNA was quantified using Nano-
Drop (Thermo Scientific), and 100 ng of total DNA was assayed using
SYBR green PCR master mix (Bio-Rad). The thermal cycling conditions
consisted of an initial denaturation step of 15 min at 95°C, followed by 30
cycles of denaturation at 94°C for 45 s, annealing for 45 s at 56°C, and
extension at 72°C for 45 s. B. longum 35624 DNA concentrations were
quantified using the absolute quantitation protocol of the ABI 7900 fast
real-time PCR system (Applied Biosystems). In a parallel experiment,
healthy BALB/c mice (6 mice per group) were gavaged with B. longum
35624 or its isogenic derivative for 3 weeks as described above for the
colitis study.
Following euthanasia on day 26, mesenteric lymph nodes were iso-
lated in order to obtain single-cell suspensions. Lymph nodes were me-
chanically disrupted using a syringe plunger to grind the nodes on a nylon
cell strainer (70 m). The strainer was washed with PBS, and the single-
cell suspensions were centrifuged at 300 g for 10 min. Cell pellets were
resuspended in 1 ml of cRPMI medium (Sigma), and cells were counted
using a Scepter cell counter (Millipore, Billerica, MA). Cells were diluted
to a final density of 1 106 cells ml1 in cRPMI, and cells were dispensed
in propylene tubes for fluorescence-activated cell sorting (FACS) staining.
Following removal of epithelial cells and collagenase VIII/DNase I
(Roche) digestion of the tissue, lamina propria mononuclear cells were
isolated as described previously (29). At the end of the process, cells were
counted using the Scepter cell counter (Millipore) and diluted to a final
concentration of 1 106 cells ml1 in cRPMI in propylene FACS staining
tubes.
OVA respiratory allergy model. Female BALB/c mice (8 to 12 weeks
of age) were obtained from Charles River and were maintained under
specific-pathogen-free conditions at the AO Research Institute, Davos,
Switzerland, in individually ventilated cages for the duration of the study.
All experimental procedures were carried out in accordance with Swiss
law (permit number 2013_20). Eight mice per group were used in this
model. Three intraperitoneal immunizations with 50 g of ovalbumin
(OVA, grade V	 98%; Sigma) emulsified in Imject alum adjuvant (Life
Technologies, Carlsbad, CA) were performed on days 0, 14, and 21, fol-
lowed by OVA aerosol challenges on days 26, 27, and 28. On days 19, 25,
and 27, mice received B. longum 35624 or sEPSneg intranasally (
1 109
bacteria per dose in a total volume of 50 l of PBS). Bacterial cells were
prepared as described above. Control animals received three intraperito-
neal injections with alum adjuvant (without OVA) on days 0, 14, and 21,
followed by OVA aerosol challenges on days 26, 27, and 28. Control ani-
mals also received 50 l of PBS intranasally on days 19, 25, and 27. All
mice were sacrificed at day 29 for isolation of lung tissue and flow cyto-
metric staining. Lung-derived single-cell suspensionswere obtained using
a combination of enzymatic digestion (lung dissociation kit, Miltenyi)
and mechanical dissociation with a gentleMACS dissociator (Miltenyi)
according to the manufacturer’s protocol. Lung cells were plated at 1 
106 cells/ml in complete RPMI (Sigma) and stimulated ex vivo with 50
g/ml OVA, grade VI (Sigma) or with 500 ng/ml LPS (Sigma) for 48 h,
and cytokine secretion quantified by using the Bio-Plex multiplex system
(Bio-Rad).
Flow cytometry. All flow cytometry analyses were performed on the
Gallios flow cytometer (Beckman Coulter, La Brea, CA). Mesenteric
lymph node or lung single-cell suspensions were stimulated with phorbol
myristate acetate (PMA) and ionomycin at 50 ng ml1 and 500 ng ml1,
respectively, for 4 h in the presence of brefeldin A (eBioscience). The
viability dye eFluor780 (eBioscience) and the following surface-staining
antibodies were used: PE-Cy7 anti-mouse CD3 antibody and Pacific blue
anti-mouseCD4 antibody (BioLegend, SanDiego,CA). Cells were stained
for intracellular cytokines using PE anti-mouse IL-10 antibody, Alexa
Fluor 488 anti-mouse/rat IL-17A antibody, and peridinin chlorophyll
protein (PerCP)-Cy5.5 anti-mouse interferon (IFN-) antibody after fix-
ation and permeabilization (intracellular fixation and permeabilization
buffer set; eBioscience). Lamina propria cells were in addition stained for
the gut-homingmoleculeCCR9usingAlexa Fluor 647 anti-mouseCD199
antibody (CCR9) from BioLegend.
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Statistical analysis. Unless otherwise indicated, data are presented as
box-and-whisker plots with the median values and maximum/minimum
values illustrated. In experiments with technical replicates, the mean was
calculated from the technical replicates for each donor and only the mean
value was used for the statistical analysis. The Mann-Whitney U test was
used for the nonparametric statistical analysis of differences between two
groups. For analysis of more than two groups, statistical significance was
determined using the Kruskal-Wallis test and Dunn’s multiple-compari-
son test. A two-way analysis of variance (ANOVA) was used to compare
groups over time. A P value of less than 0.05 was considered statistically
significant.
RESULTS
Generation of an isogenic exopolysaccharide-negative deriva-
tive of B. longum 35624, designated sEPSneg, by insertion mu-
tagenesis. In order to determine the role, if any, of the exopoly-
saccharide in the reported immunomodulatory activities of the B.
longum 35624 strain, we set out to generate an isogenic derivative
of this strain that was unable to produce this cell surface-associ-
ated glycan exopolymer. For this purpose, we employed a mu-
tagenesis strategy that was based on previously describedmethods
(30). The particular mutagenesis strategy employed for B. longum
35624 involved the heterologous expression of a B. longum 35624-
encoded DNAmethylase in E. coli strain EC101 so as to methylate
any plasmid DNA in the latter cloning host. When such methyl-
ated plasmid DNA is subsequently introduced into B. longum
35624, it will be protected fromdigestion by the native restriction-
modification systems encoded by the latter strain and will there-
fore allow homology-guided, site-directed mutagenesis as has
been described previously (30). Employing this strategy, we cre-
ated an insertion mutation in the first gene of the EPS624 cluster,
i.e., pgt624, encoding the predicted priming glycosyl transferase
(pGT), resulting in an isogenic derivative of B. longum 35624 that
was designated sEPSneg.
In order to assess whether the sEPSneg mutant had, as would be
expected, lost its ability to produce exopolysaccharide, we per-
formed electron microscopy analysis, which indeed revealed that
the “stringy”-appearing sEPS layer present on the parent strain B.
longum 35624 is absent on sEPSneg, thus confirming its exopoly-
saccharide-deficient phenotype (Fig. 1). Furthermore, and in con-
trast to the parent strain B. longum 35624, the sEPSneg strain ex-
hibits a so-called dropping phenotype when grown in liquid
medium (i.e., the sEPSneg strain was found to sediment during
growth in liquid medium, but the B. longum 35624 strain re-
mained in suspension). A similar phenotype was observed for ex-
opolysaccharide-negative variants of B. breve UCC2003 and Bifi-
dobacterium animalis subsp. lactis (21, 31), thereby substantiating
the loss of exopolysaccharide production. To ensure that the ob-
served phenotype is directly linked to the inactivation of pgt624, the
adjacent and cotranscribed genes pgt624 and BI0343 were cloned
together with the presumed promoter sequence in plasmid
pBC1.2, after which the resultant construct was introduced into
the sEPSneg strain. The resulting strain, designated sEPScomp, was
shown to produce exopolysaccharide (Fig. 1). A similar comple-
mentation approach was described previously (32, 33). The sEP-
Sneg and sEPScomp mutants grew more slowly than the parent
strain B. longum 35624, likely due to the presence of antibiotics in
their culture medium, but by 38 h of culture, all bacteria were at
similar numbers and had reached stationary phase (see Fig. S1 in
the supplemental material).
In vitro responses to B. longum 35624, sEPSneg, and
sEPScomp.Thewild-type strainB. longum 35624 and its derivatives
sEPSneg and sEPScomp were coincubated with human PBMCs for
24 h, followed by analysis of cytokine secretion in cell-free super-
natants. Compared with B. longum 35624, the sEPSneg strain was
shown to induce higher levels of IL-12p70, IFN-, and IL-17 se-
cretion but comparable levels of IL-10 (Fig. 2A). The sEPScomp
strain induced cytokine secretion at levels similar to their induc-
tion byB. longum 35624, confirming that enhanced proinflamma-
tory cytokine secretion is specifically associated with the lack of
exopolysaccharide production. The addition of isolated exopoly-
saccharide to the cocultures significantly reduced IL-12p70 and
IFN- secretion in response to the sEPSneg strain but did not alter
the IL-17 or IL-10 response to the sEPSneg strain (Fig. 2B).
Similarly to PBMCs, humanMDDCs were coincubated with
B. longum 35624 or sEPSneg strains, and cytokine secretion was
measured after a 24-h exposure. Secreted IL-17, IL-6, and tumor
necrosis factor alpha (TNF-) levels, but not IL-10,were all shown
to be significantly higher for the sEPSneg-stimulatedMDDCs than
for the B. longum 35624 -stimulated MDDCs (Fig. 3A). In con-
trast, no differenceswere found in theB. longum 35624 or sEPSneg-
induced expression of the MDDC inhibitory molecules pro-
grammeddeath ligand-1 (PD-L1) andPD-L2, which bind to PD-1
on activated lymphocytes and play an important role in down-
regulating the immune system (Fig. 3B).
Activation of the transcription factor NF-B is critical for the
induction of inflammatory genes, including cytokines. Thus, we
FIG 1 Electronmicroscopy of B. longum 35624. Representative scanning elec-
tron microscopy (SEM) images for the B. longum 35624 parent strain (A) and
its isogenic derivatives sEPSneg (B) and sEPScomp (C). Arrows indicate the
stringy-appearing layer of extracellular polysaccharide visible on theB. longum
35624 parent strain and the sEPScomp strain. Scale bars are indicated at the
bottom right of each panel.
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measuredNF-B activation in themonocyte cell line THP-1, con-
taining a SEAP reporter for NF-B and AP-1 activation. The
sEPSneg strain was shown to induce higher levels of NF-B/AP-1
activation than B. longum 35624 in THP-1 cells (Fig. 3C). To con-
firm this result, NF-Bphosphorylationwasmeasured inMDDCs
over time, following exposure to bacteria. Both B. longum 35624
and sEPSneg induced similar levels of NF-B phosphorylation at
early time points (Fig. 3D). However, sustained high levels of
phosphorylated NF-B were observed at later time points for the
sEPSneg-stimulated MDDCs, which were not observed for B.
longum 35624-stimulated cells.
Taken together, these results suggest a role for this exopolysac-
charide in preventing in vitro inflammatory responses to B.
longum 35624.
The sEPSneg strain does not protect against colitis develop-
ment. Colitis was induced in SCID mice by adoptively transfer-
ring CD4 CD25 CD45RBhi lymphocytes. Mice were adminis-
tered B. longum 35624, sEPSneg, or sEPScomp daily by oral gavage.
As previously described, B. longum 35624 treatment prevented
weight loss and disease symptoms in this model (34). However,
mice treated with the sEPSneg strain exhibited significant weight
loss and severe disease symptoms, while restoration of EPS pro-
duction in the sEPScomp strain promoted a response similar to that
of mice treated with B. longum 35624 (Fig. 4A). Following eutha-
nasia, the colon/body weight ratio was significantly higher in an-
imals administered the sEPSneg strain, while macroscopically, the
colons of these mice appeared severely inflamed with visible ne-
crotic regions, which was not observed when animals had been
administered B. longum 35624 (Fig. 4B). Within the mesenteric
lymph nodes, there were significantly more IL-17 lymphocytes
in animals administered sEPSneg, with a trend toward increased
numbers of IFN- lymphocytes which was not statistically sig-
FIG 2 PBMC cytokine response to bacterial strains. (A) PBMCs from 6 healthy donors were stimulated with B. longum 35624 or its isogenic derivatives sEPSneg
or sEPScomp (50 bacteria/1 PBMC) for 24 h, and cytokine secretion into the culture supernatant was quantified. Data are presented as box-and-whisker plots with
the median values and maximum/minimum values illustrated. Statistical significance was determined using the Kruskal-Wallis test and Dunn’s multiple-
comparison test (*, P 0.05). (B) Effect of adding isolated exopolysaccharide on sEPSneg strain-induced PBMC secretion of IL-12p70, IFN-gamma, IL-17, and
IL-10. Each line connects the data for PBMC from the same donor. TheMann-Whitney U test was used for the statistical analysis (*, P 0.05 versus the sEPSneg
strain alone). Error bars show standard deviations.
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nificant (Fig. 4C). No significant difference in IL-10 lympho-
cytes was observed. No difference in the gastrointestinal transit of
B. longum 35624 or the sEPSneg derivative was observed (see Fig.
S2 in the supplemental material).
The administration of the sEPSneg strain to healthy immuno-
competent animals did not result in gastrointestinal inflamma-
tion, indicating that the sEPSneg mutant did not induce colitis in
healthy animals. However, the administration of sEPSneg did pro-
voke a trend to increased percentages of IL-17 and IFN- lym-
phocytes, associated with an increase in CCR9 T cells, within the
lamina propria of healthy animals, although these differences did
not reach statistical significance (see Fig. S3 in the supplemental
material). These data suggest that an inflamedmicroenvironment,
such as that present in the SCID model, is required for sEPSneg to
exert its TH17-enhancing effects.
sEPSneg exacerbates IL-17 responseswithin the lung. In order
to further assess the ability of sEPSneg to promote IL-17 responses
in vivo, we utilized the ovalbumin (OVA) sensitization and respi-
ratory challenge model, as we and others previously evidenced
potent TH17 responses within the lungs of challenged animals
(35). Either B. longum 35624 or its isogenic derivative sEPSneg was
administered intranasally to examine the influence of these strains
on IL-17 responses within the lung. OVA sensitization and chal-
lenge resulted in an increased percentage of IL-17 lymphocytes
within lung tissue compared to the level in control animals (Fig.
5A). Exposure to the B. longum 35624 strain did not influence the
FIG 3 MDDC response to bacterial strains. MDDCs were generated from 4 healthy donors and were stimulated with B. longum 35624 or its isogenic derivative
sEPSneg (50 bacteria/1 MDDC) for 24 h. (A and B) Cytokine secretion into the culture supernatant (A) and cell surface expression of the inhibitory molecules
PD-L1 and PD-L2 (B) were quantified. Data are presented as box-and-whisker plots with the median values and maximum/minimum values illustrated. The
Mann-Whitney U test was used for the statistical analysis (*, P 0.05 B. longum 35624 versus the sEPSneg strain). (C) NF-B activation in THP-1 cells following
exposure to increasing concentrations of B. longum 35624 or its isogenic derivative sEPSneg (n 4 experimental replicates). (D) Activation of NF-B inMDDCs
exposed to B. longum 35624 or its isogenic derivative sEPSneg (n 3, 50 bacteria/1 MDDC). Statistical significance was determined using two-way ANOVA (*,
P 0.05 B. longum 35624 versus the sEPSneg strain). Error bars show standard deviations.
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percentage of IL-17 lymphocytes within the lung; however, ex-
posure to sEPSneg significantly increased the percentage of IL-17
lymphocytes (Fig. 5A). Single-cell suspensions were generated
from the lungs of all animals challenged as indicated above, and
these lung cells were restimulated ex vivo with OVA or LPS to
assess IL-17 secretion. OVA-sensitized and challenged animals
displayed increased ex vivo secretion of IL-17 in response to both
OVA and LPS stimulation compared to the levels in nonsensitized
animals, suggesting that innate TLR-4 responses to LPS and aller-
gen-specific lymphocyte responses to OVA are increased in the
inflamed lungs of allergic animals (Fig. 5A). The in vivo exposure
to B. longum 35624 did not alter the ex vivo secretion of IL-17 by
lung cells stimulated with either LPS or OVA.However, if animals
had been exposed to sEPSneg in vivo previously, the isolated lung
cells secreted significantly more IL-17 ex vivo in response to both
TLR-4 stimulation with LPS and allergen restimulation withOVA
(Fig. 5A). Thus, the ex vivo secretion of IL-17 and the percentage of
IL-17 cells within lung tissue correlate with the highest levels for
both assay systems being observed for sEPSneg-treated animals.
OVA sensitization and challenge resulted in an increased per-
centage of IFN- lymphocytes within lung tissue compared to
the level in control animals (Fig. 5A). Exposure to the B. longum
35624 strain prevented the increase in the percentage of IFN-
lymphocytes within the lung, which was not observed following
exposure to the sEPSneg strain (Fig. 5B). Restimulation of lung
single-cell suspensions ex vivo with OVA or LPS did not result in
significant levels of IFN- being secreted, and no statistically sig-
nificant differences were observed between the groups (Fig. 5B).
OVA sensitization and challenge resulted in an increased per-
centage of IL-10 lymphocyteswithin lung tissue, and exposure to
FIG4 sEPSneg is not protective in aT cell transfer colitismodel. Following receipt of CD4CD25CD45RBhi T cells, C.B-17 SCIDmicewere orally administered
B. longum 35624 (n  8), sEPScomp (n  8), or sEPSneg (n  8). (A) Weight loss and disease activity were monitored over time. Statistical significance was
determined using two-wayANOVA (*,P 0.05). (B) Following euthanasia, the colon/bodyweight ratiowas determined. A representative picture of colons from
B. longum 35624- and sEPSneg-treated animals is provided. (C) The percentages of IL-17, IFN-, and IL-10 lymphocytes frommesenteric lymph nodes are
illustrated (n 8 mice per group). Data are presented as box-and-whisker plots with the median values and maximum/minimum values illustrated. Statistical
significancewas determinedusing theKruskal-Wallis test andDunn’smultiple-comparison test (*,P 0.05 for sEPSneg strain versus the other strains). Error bars
show standard deviations.
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B. longum 35624 or the sEPSneg strains further increased the per-
centage of IL-10 lymphocytes within the lung (Fig. 5C). Re-
stimulation ex vivowas also associated with increased secretion of
IL-10 following in vivo exposure toB. longum 35624 or the sEPSneg
strains (Fig. 5C).
These findings suggest that the absence of the exopolysaccha-
ride onB. longum 35624 promotes TH17 responses in the inflamed
lung, similar to the effects described above for the inflamed gut.
DISCUSSION
In order to avoid immune-mediated destruction of mucosal tis-
sues, the host can activate regulatory mechanisms that can block
proinflammatory responses to commensal microbes present on
mucosal surfaces. Bifidobacteria comprise a significant propor-
tion of the gut microbiota, and many strains are currently used as
probiotics. However, the precise mechanisms by which such bifi-
dobacteria interact with host immune cells are not fully under-
stood. In this report, we describe that the presence of a cell surface-
associated exopolysaccharide produced by B. longum 35624
modulates cytokine secretion andNF-B activation in vitro, while
inmurinemodels, exposure to aB. longum 35624 derivative that is
unable to synthesize exopolysaccharide promotes TH17 responses
within both the gut and the lung.
Bifidobacterial cell surface-associated exopolysaccharides have
previously been proposed to (i) mediate some of the health-pro-
moting benefits of these bacteria, (ii) contribute to bifidobacterial
tolerance of the harsh conditions within the gut, and (iii) influ-
ence the composition of the gut microbiome through their use as
a fermentable substrate by othermicrobes (21, 36–38). In general,
bacterial exopolysaccharides consist of repeating mono- or oligo-
saccharide subunits connected by various glycosidic linkages that
are structurally very diverse and may contribute to strain-specific
traits due to the expected structural and, therefore, functional
diversity of such molecules. Of note, pathogen-associated exopo-
lysaccharides have long been known to be critical in host-microbe
interactions, where they facilitate adherence and colonization
FIG 5 sEPSneg promotes TH17 responses in the lung. Nonsensitized animals received an OVA aerosol challenge and were administered PBS intranasally
(Control, n 8). Sensitized animals received an OVA aerosol challenge and were administered PBS (OVA, n 8), B. longum 35624 (OVA & 35624, n 8), or
sEPSneg (OVA& sEPSneg, n 8) intranasally. (A) Percentages of IL-17CD3CD4 T lymphocytes isolated from lung tissue and secretion levels of IL-17 from
isolated lung cells restimulated ex vivowithOVAor LPS. (B andC) IFN- (B) and IL-10 (C)CD3CD4T lymphocytes and ex vivo IFN- and IL-10 secretion
were quantified using identical methods. Data are presented as box-and-whisker plots with the median values and maximum/minimum values illustrated.
Statistical significance was determined using the Kruskal-Wallis test and Dunn’s multiple-comparison test (*, P 0.05 compared to the OVA group). Error bars
show standard deviations.
B. longum Exopolysaccharide Modulates TH17 Responses
December 2016 Volume 82 Number 24 aem.asm.org 7193Applied and Environmental Microbiology
 o
n
 D
ecem
ber 5, 2016 by UZH Hauptbibliothek / Zentralbibliothek Zuerich
http://aem
.asm
.org/
D
ow
nloaded from
 
within the human host, with additional immunomodulatory ef-
fects (39, 40). Exopolysaccharides can also mediate the beneficial
immune effects associated with certain commensal microbes. As
already mentioned, a strong modulator of intestinal immune re-
sponses is PSA fromB. fragilis, which is well described to influence
lymphocyte polarization and which suppresses IL-17 production
by intestinal immune cells (41–43). In line with data presented
here, exopolysaccharide gene knockout mutants of Lactobacillus
casei Shirota induced significantly more proinflammatory cyto-
kine secretion from a mouse macrophage cell line than did wild-
type cells (44). In addition, the cytokine response of PBMCs to two
isogenic strains of B. animalis subsp. lactis that differ only in their
exopolysaccharide-producing phenotype suggest that the mucoid
strain could have greater anti-inflammatory activity (31). The
data presented here are in agreement with these previous reports
and further support the concept that exopolysaccharides from
bifidobacteria may elicit immune-modulatory activities.
Interestingly, the induction of PD-L1 and PD-L2 on dendritic
cells was similar for the wild-type B. longum 35624 strain and its
isogenic derivative, sEPSneg. Similarly, the induction of IL-10 was
not negatively impacted by the loss of exopolysaccharide from the
bacterium. This suggests that not all immune-regulatory effects
induced by B. longum 35624 are mediated solely by exopolysac-
charide. The bifidobacterial cell wall is a complex arrangement of
macromolecules, consisting of a thick peptidoglycan layer that
surrounds the cytoplasmic membrane, which is decorated with
other glycopolymers, such as (lipo)teichoic acids, polysaccha-
rides, and proteins, all of which may influence the immune re-
sponse (45, 46) A few examples include the cell wall-associated
proteins p40 and p75 from L. casei subsp. rhamnosus GG, the
S-layer protein from Lactobacillus acidophilus, and the STp pep-
tide from Lactobacillus plantarum (47–49).
TH17 cells are a subset of CD4
 T helper cells that mediate
protective immunity to extracellular bacterial and fungal patho-
gens, predominantly at epithelial surfaces (50). Polarization of
naive T cells into TH17 cells occurs following T-cell antigen recep-
tor recognition of a major histocompatibility complex (MHC)
class II-bound peptide in the presence of cytokines, including
transforming growth factor 1 (TGF-1), IL-6, or IL-1 (51, 52).
While TH17 cells are required for protective immunity, these cells
massively infiltrate the inflamed intestine of inflammatory bowel
disease patients, where they produce IL-17 and other cytokines,
triggering and amplifying the inflammatory process (53). Our
data suggest that the B. longum 35624 strain-associated exopoly-
saccharide prevents the induction of a TH17 response to this bac-
terium.Multiplemechanismsmay be involved in this process. For
example, the exaggerated induction of cytokines, including IL-6,
from dendritic cells may support TH17 lymphocyte polarization
and development. Support for this hypothesis can be seen when
we restimulate OVA-specific T cells with OVA and observe in-
creased secretion of IL-17when the lungs were previously exposed
to sEPSneg. These OVA-specific T cells are not reacting to bifido-
bacterium-associated antigens, but more IL-17 is secreted upon
OVA challenge, suggesting that it is the cytokine microenviron-
ment provided by innate cells such as dendritic cells that is sup-
porting excessive TH17 development. The observation that the
addition of purified exopolysaccharide to sEPSneg-stimulated
PBMCs suppresses the exaggerated IL-12p70 and IFN- secretion
but not IL-17 secretion also suggests that multiple mechanisms
may be involved. Future studies will determine whether it is the
exopolysaccharide itself that can directly inhibit TH17 responses
by binding to host receptors or whether the exopolysaccharide is
simply masking TH17-promoting molecules on the surface of this
bacterium.
In conclusion, we have identified a novel immunoregulatory
activity associated with the presence of a exopolysaccharide in the
human commensal B. longum strain 35624. Our findings suggest
that this exopolysaccharide is required to prevent a potent tissue-
damaging TH17 response to a commensal bacterium. Accord-
ingly, our data on the B. longum 35624-associated exopolysac-
charide corroborate and expand the published concept that
exopolysaccharides produced by certain lactic acid bacteria and
bifidobacteria may elicit immune-modulatory activities (54) that
are important for appropriate host-microbe communication.
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